QLT Inc.: Clinical Trials

6 completed, 1 terminated. 7 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 6, Terminated 1
Phase 2	2	Completed 2

Follow QLT Inc.: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) QLT091001 - Retinitis Pigmentosa (RP)	Phase 1	Completed	QLT Inc.	5	2012-02-01	2014-12-15
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) QLT091001 - LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)	Phase 1	Completed	QLT Inc.	27	2012-01-01	2014-07-28
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations QLT091001 - LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)	Phase 1	Completed	QLT Inc.	32	2009-11-01	2013-05-14
Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers QLT091001 - Healthy Human Volunteers	Phase 1	Completed	QLT Inc.	18	2008-09-01	2009-03-30
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Verteporfin Therapy/ Drug: Bevacizumab - Macular Degeneration	Phase 1	Terminated	Vitreous -Retina- Macula Consultants of New York	10	2006-09-01	2008-07-30
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia QLT0074, Photodynamic therapy - Benign Prostatic Hyperplasia	Phase 1 / Phase 2	Completed	QLT Inc.		2003-03-01	2012-05-23
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma Detox-B adjuvant, verteporfin - Melanoma (Skin)	Phase 1 / Phase 2	Completed	QLT Inc.		2000-10-01	2013-11-06

Conditions studied

Retinitis Pigmentosa (3)  ·  Leber Congenital Amaurosis (2)  ·  Macular Degeneration (1)  ·  Melanoma (1)  ·  Prostatic Hyperplasia (1)

Interventions

retinol acetate (4)  ·  Photochemotherapy (1)  ·  QLT0074 (1)  ·  Verteporfin (1)  ·  detox adjuvant (1)

Countries

Canada (5)  ·  United States (5)  ·  Germany (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Ireland (1)

Top investigators

Sushanta Mallick (3)  ·  Andrew Strong, Ph.D. (1)  ·  Graeme R. Boniface, PhD (1)  ·  Jason S Slakter, M.D. (1)  ·  Victor Lao, MD (1)

Results publications

PMID 25030840, PMID 26448901, PMID 26656277, PMID 32573764